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An empirical reappraisal of public trust in
biobanking research: Rethinking restrictive
consent requirements
Wendy Lipworth, Bronwen Morrell, Rob Irvine and Ian Kerridge*
Collections of human tissue removed from patients in the course of medical
diagnosis or therapy are believed to be an increasingly important resource for
medical research (biobank research). As a result of a number of tissue-
related “scandals” and increasing concern about ownership and privacy, the
requirements to obtain consent from tissue donors are becoming increasingly
stringent. The authors’ data show that members of the general public
perceive academic biobank researchers and their institutions to be highly
trustworthy and do not see the need for recurrent, project-specific consent.
They argue, on the basis of their empirical findings, that we should question
the trend, at least in some settings, toward ever more stringent consent
requirements for the use of tissue in research. They argue that this approach,
while perhaps counterintuitive in the current regulatory environment, can be
both ethically and legally sound so long as channels of communication are
maintained and third-party relationships are tightly controlled.
BACKGROUND
Stored collections of diseased human tissue (biobanks) are thought by many scientists to be an
essential resource for medical research (biobanking research).1 In general terms, tissue removed from
patients in the course of medical diagnosis or therapy is stored in biobanks. This tissue provides a
means by which abnormalities in tissue (usually genetic patterns) can be correlated with disease
aetiology, prognosis and treatment responsiveness. Despite its promise, biobanking research has raised
a number of challenging ethical issues, particularly in relation to the means of obtaining consent for
the storage and use of tissues, the management of donor (genetic) privacy, and the ownership of the
tissue and the products of tissue-based research.
In recent years, there has been a series of scandals involving the non-consensual retention of
organs and tissues during post-mortem examinations in both the United Kingdom2 and Australia,3 as
well as negative public reactions to population genetic databases which presume consent4 and legal
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conflict over ownership of tissue used for the development of cell lines.5 These cases have led to an
examination of all types of biobanking practices and the development of new human tissue and
privacy legislation.6
As a result of these episodes, and of concerns about genetic privacy more generally, regulation of
biobanking research has become increasingly stringent. This regulation has focused particularly on the
consent that needs to be obtained from potential donors. While some ethical and legal codes in
Australia7 and the United Kingdom8 allow for open-ended consent to unspecified future research and
outline criteria for waiving project-specific consent, there are increasing demands on ethics
committees to report and justify their decisions to waive consent.
This demand for increasingly stringent consent in the context of biobanking is a highly contested
issue. This is perhaps most evident in the ongoing debates in the scientific and bioethical literature;9 in
differences among international legal and ethical codes;10 and in the variability of approaches to
consent taken by biobanks.11 Given the highly contested nature of these issues, it is important to
understand not only the abstract ethical and legal issues raised by tumour-banking, but also the beliefs
and values of those involved, including the reasons why people are motivated to donate or, rarely, to
refuse such donation; the extent to which people privilege personal autonomy over scientific progress;
and the degree to which donors trust biobank researchers.
JUSTIFICATION FOR A QUALITATIVE ANALYSIS OF PUBLIC TRUST IN BIOBANKING
RESEARCH
There is an assumption in much of the theoretical literature on biobanking that the public is
increasingly distrustful of biobank researchers and of academic biomedicine more generally.12 The
angry public reaction to the “scandals” involving the non-consensual retention of human tissue and
organs, concerns about population biobanks and other tissue-related controversies, is frequently used
to justify the claim that the public is distrustful of biobanking researchers.13 This view of public trust
is situated within a more general and longstanding belief that the public is ambivalent towards all
5 For example, Moore v Regents of the University of California 793 P 2d 479 (1990). See Ashburn T, Wilson S and
Eisenstein B, “Human Tissue Research in the Genomic Era of Medicine” (2000) 160 Arch Intern Med 3377.
6 Stranger M, Chalmers D and Nicol D, “Capital, Trust & Consultation: Databanks and Regulation in Australia” (2005) 15
Crit Publ Health 349.
7 National Health and Medical Research Council, National Statement on Ethical Conduct in Research Involving Humans
(NHMRC, Canberra, 2007).
8 United Kingdom, Department of Health, The Human Tissue Act 2004: New Legislation on Human Organs and Tissue (2004).
9 Furness P, “The Human Tissue Bill: Criminal Sanctions Linked to Opaque Legislation Threaten Research” (2004) 328 BMJ
533; Savulescu J, “No Consent Should be Needed for Using Leftover Body Material for Scientific Purposes” (2002) 325 BMJ
648; Sobel M, “Ethical Issues in Molecular Pathology: Paradigms in Flux” (1999) 123 Arch Pathol Lab Med 1076; Bauer K,
Taub S and Parsi K, “Ethical Issues in Tissue Banking for Research: A Brief Review of Existing Organizational Policies” (2004)
25 Theor Med Bioeth 113.
10 Artizzu, n 4; Bauer, Taub and Parsi, n 9; Wright Clayton E, “Informed Consent and Biobanks” (2005) 33 J Law Med Ethics
15.
11 Clark G, Lipworth W, Bokey L, Little JM and Kerridge I, “An Empirical Study of Tissue Banking in Australia: Navigating
Regulatory and Ethical Challenges” (2006) 14 JLM 102; Chadwick R and Berg K, “Solidarity and Equity: New Ethical
Frameworks for Genetic Databases” (2001) 2 Nat Rev Genet 318; Gibson E, Brazil K, Coughlin MD, Emerson C et al, “Who’s
Minding the Shop? The Role of Canadian Research Ethics Boards in the Creation and Uses of Registries and Biobanks” (2008)
9 BMC Med Ethics 17; Hirtzlin Dubreuil C, Préaubert N, Duchier J et al, “An Empirical Survey on Biobanking of Human
Genetic Material and Data in Six EU Countries” (2003) 11 Eur J Hum Genet 475.
12 Levitt M and Weldon S, “A Well Placed Trust? Public Perceptions of the Governance of DNA Databases” (2005) 15
Crit Publ Health 311.
13 Hansson M, “Building on Relationships of Trust in Biobank Research” (2005) 31 J Med Ethics 415; Mason K and Laurie G,
“Consent or Property? Dealing with the Body and Its Parts in the Shadow of Bristol and Alder Hey” (2001) 64 Mod L Rev 710;
Haddow G, Cunningham-Burley S, Bruce A and Parry S, “Generation Scotland: Consulting Publics and Specialists at an Early
Stage in a Genetic Database’s Development” (2008) 18 Crit Publ Health 139; Stranger, Chalmers and Nicol, n 6; Levitt and
Weldon, n 12; Ashburn, Wilson and Eisenstein, n 5; Hoeyer K, “The Power of Ethics: A Case Study from Sweden on the Social
Life of Moral Concerns in Policy Processes” (2006) 28 Sociol Health Illn 785.
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kinds of expertise and the institutions that employ expert knowledge (of which academic biomedicine
and its biobanking “branch” is just one example).14 Governments, too, see the need for public
consultation and accountability as a means of increasing or securing public trust in biobanking
research.15 On the other hand, there is the view that people have high and stable levels of trust in
health professionals and public “medical research” bodies (as compared to, eg, industry) on the
understanding that their interests will be protected,16 and that this trust needs to be maintained rather
than restored.17
It is possible to speculate endlessly about the level of public trust in science in general and
biobanking research in particular, but if regulation is to be responsive to the population, it is necessary
to know exactly how high, and how stable, trust actually is. We cannot simply assume that the public
is mistrustful (or likely to become mistrustful) of scientists – an assumption that is often used, along
with autonomy, to justify increasingly stringent consent requirements,18 nor can we assume that trust
is high. It is also important to know which entities are trusted (so that control can be placed in the
appropriate hands). As Baier observes, “any form of cooperative activity … requires the cooperators to
trust one another to do their bit, or at the very least to trust the overseer with his whip to do his bit”.
There is always somebody who has the potential to do us harm and who, therefore, needs to be
trusted,19 and it is important to ascertain who this “somebody” should be.
Existing empirical research provides some clues. On the one hand, several empirical studies of
biobanking have suggested high levels of public trust, or confidence, in the context of biobanking,
with risks being seen as low or likely to be well managed through existing regulatory systems.20
Hoeyer observes that donors do not ask for much information, nor do they read all of the information
provided, and this is interpreted as an “expression of trust”.21 Indeed, the mere fact of donation in the
face of potential risk has been interpreted as an expression of trust.22 As Hoeyer and Lynoe point out,
14 Bauman Z, Mortality, Immortality and Other Life Strategies (Polity Press, Cambridge, 1992); Barsky A, Worried Sick: Our
Troubled Quest for Wellness (Little Brown, Boston, 1988); Crawford R, “Risk Ritual and the Management of Control and
Anxiety in Medical Culture” (2004) 8 Health 505; Hacking I, The Taming of Chance (Cambridge University Press, Cambridge,
1990); Sontag S, Illness as Metaphor (Farrar, Starus & Giroux, New York, 1978); Bauman Z, In Search of Politics (Stanford
University Press, Stanford, 1999); Beck U, Risk Society: Towards a New Modernity (trans R Ritter, Sage Publications, London,
1992); Giddens A, Modernity and Self-Identity (Polity Press, Cambridge, 1991); Wynne B, “May the Sheep Safely Graze? A
Reflexive View of the Expert-Lay Knowledge Divide” in Lash S, Szerszinski B and Wynne B (eds), Risk, Environment and
Modernity: Towards a New Ecology (Sage Publications, London 1996).
15 Stranger, Chalmers and Nicol, n 6; Haddow, Cunningham-Burley, Bruce and Parry, n 13; Levitt and Weldon, n 12; Tutton R,
Kaye J and Hoeyer K, “Governing UK Biobank: The Importance of Ensuring Public Trust” (2004) 22 Trends Biotechnol 284.
16 Levitt and Weldon, n 12.
17 Ashburn, Wilson and Eisenstein, n 5.
18 Petersen A, “Securing Our Genetic Health: Engendering Trust in UK Biobank” (2005) 27 Sociol Health Illn 271; Levitt and
Weldon, n 12; Hoeyer, n 13.
19 Baier A, “Trust and Antitrust” (1986) 96 Ethics 231 at 232.
20 Barr M, “‘I’m Not Really Read Up on Genetics’: Biobanks and the Social Context of Informed Consent” (2006) 1
BioSocieties 251; Dixon-Woods M, Wilson D, Jackson C, Cavers D et al, “Human Tissue and ‘the Public’: The Case of
Childhood Cancer Tumour Banking” (2008) 3 BioSocieties 57; Dixon-Woods M, Ashcroft RE, Jackson CJ, Tobin MD et al,
“Beyond ‘Misunderstanding’: Written Information and Decisions About Taking Part in a Genetic Epidemiology Study” (2007)
65 Soc Sci Med 2212; Ormond KE, Cirino AL, Helenowski IB, Chisholm RL et al, “Assessing the Understanding of Biobank
Participants” (2009) 149A Am J Med Genet Pt A 188; Richards MPM, Ponder M, Pharoah P, Everest S et al, “Issues of Consent
and Feedback in a Genetic Epidemiological Study of Women with Breast Cancer” (2003) 29 J Med Ethics 93; Treloar SA,
Morley KI, Taylor SD and Hall WD, “Why Do They Do It? A Pilot Study Towards Understanding Participant Motivation and
Experience in a Large Genetic Epidemiological Study of Endometriosis” (2007) 10 Community Genet 61.
21 Hoeyer, n 13 at 790.
22 Hoeyer, n 13.
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people’s “willingness to donate blood and healthcare information … shows that most people do not
see themselves as engaged in a contractual relationship. Instead, they still seem to perform a duty
embedded in trust and mutual obligations.”23
On the other hand, there is empirical evidence of waning public confidence in science in general24
and of biobanking in particular,25 and of less willingness to contribute to biobanks following
tissue-related scandals.26 And concerns about confidentiality, commercialisation and control of tissue
samples in population DNA databases have emerged as important issues in some recent consultative
empirical work.27 In some studies, levels of trust were seen to vary; and the level of trust was seen to
be the main determinant of participants’ willingness to cooperate with biobanking.28 Some studies
have shown that trust in some entities (such as academic researchers) is higher than trust in others
(such as politicians and private companies).29
None of these studies have, however, defined exactly what is meant by trust or analysed data
systematically with a particular definition in mind. This is significant, given that trust can have many
meanings, with “connotations of faith, commitment, a general expression of respect, belief and
confidence” and may be “learnt, contextual, specific, scalar, rationally transferrable, durable
(particularly where it is based upon nonrational faith) and independent of legal notions of contracts”.30
Indeed, only if trust is clearly defined (at least for the purposes of a research project) is it possible to
know what it really means in a particular context, and to draw conclusions from its presence or
absence. As Haddow argues, it is important to “unearth accounts of what trust means to people in a
specific context and their reasons for trusting one organisation, system, or ‘expert’ over another”.31 For
this reason, the present authors undertook a qualitative study (as part of a larger mixed methods study)
of the legal, social and ethical issues surrounding tumour banking in New South Wales, Australia, with
a view to exploring (among other things) public trust in academic biobankers and their institutions.
METHODS
Sampling and recruitment
The qualitative phase of this research which is reported here involved in-depth, semi-structured
interviews with a range of lay stakeholders, which included patients (P) and parents of children (C)
who had donated tissue to a biobank, health advocates (HA), consumer representatives (CR) and
indigenous representatives (IR).
23 Hoeyer K and Lynoe N, “Motivating Donors to Genetic Research? Anthropological Reasons to Rethink the Role of Informed
Consent” (2006) 9 Med Health Care Philos 13.
24 Levitt and Weldon, n 12; Ahern M and Hendryx M, “Social Capital and Trust in Providers” (2003) 57 Soc Sci Med 1195.
25 Goodson M and Vernon B, “A Study of Public Opinion on the Use of Tissue Samples from Living Subjects for Clinical
Research” (2004) 57 J Clin Pathol 135.
26 Khong TY and Tanner AR, “Foetal and Neonatal Autopsy Rates and Use of Tissue for Research: The Influence of ‘Organ
Retention’ Controversy and New Consent Process” (2006) 42 J Paediatr Child Health 366.
27 Haddow, Cunningham-Burley, Bruce and Parry, n 13; Godard B, Marshall J and Laberge C, “Community Engagement in
Genetic Research: Results of the First Public Consultation for the Quebec CARTaGENE Project” (2007) 10 Community Genet
147; Hoeyer, n 13; Kaphingst KA, Janoff JM, Harris LN and Emmons KM, “Views of Female Breast Cancer Patients Who
Donated Biologic Samples Regarding Storage and Use of Samples for Genetic Research” (2006) 69 Clin Genet 393;
McCarty CA, Chapman-Stone D, Derfus T, Giampietro PF et al, “Community Consultation and Communication for a
Population-based DNA Biobank: The Marshfield Clinic Personalized Medicine Research Project” (2008) 146A
Am J Med Genet Pt A 3026.
28 Beskow LM and Dean E, “Informed Consent for Biorepositories: Assessing Prospective Participants’ Understanding and
Opinions” (2008) 17 Cancer Epidemiol Biomarkers Prev 1440.
29 Haddow G, Laurie G, Cunningham-Burley S and Hunter KG, “Tackling Community Concerns About Commercialisation and
Genetic Research: A Modest Interdisciplinary Proposal” (2007) 64 Soc Sci Med 272; Beskow and Dean, n 28;
Kettis-Lindblad A, Ring L, Viberth E and Hansson MG, “Genetic Research and Donation of Tissue Samples to Biobanks. What
Do Potential Sample Donors in the Swedish General Public Think?” (2006) 16 Eur J Public Health 433.
30 Kerridge I, McPhee J and Lowe M, Ethics and Law for the Health Professions (Federation Press, Sydney, 2005) p 120.
31 Haddow, Cunningham-Burley, Bruce and Parry, n 13 at 148.
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Having received ethics approval from Sydney West Area Health Service, the Children’s Hospital
at Westmead, Sydney, and the University of Sydney, lay participants were recruited through Westmead
Hospital, the Children’s Hospital at Westmead and a number of disease organisations and consumer
groups. Recruitment ceased after thematic saturation had been reached (that is, no novel issues
appeared to be emerging from the interviews).
Participants included 12 men and women aged 35 to 86. All participants identified themselves as
Australian, although several also included reference to either Anglo or Aboriginal descent. Education
levels of participants ranged from secondary school to postgraduate level, although most had some
tertiary education. Participants were asked to elaborate on whether they had encountered the idea of
biobanking before and if so in what context. The initial degree of familiarity with the concept of
biobanking varied considerably among the participants from those who were informed solely through
media coverage, to those who had themselves banked tissue for treatment and/or research and had
some knowledge of the issues involved. All participants were therefore given a brief introduction to
biobanking at the beginning of the interview to ensure that they had at least a basic understanding of
the concept.
Interviewees were asked a series of open-ended questions that allowed themes to emerge.
Open-ended questions were followed by a series of prompts to explore the issues in greater depth.
Interviews were transcribed and anonymised using randomly assigned numbers. All identifying
information was stored in locked filing cabinets and password-protected computers.
Coding and analysis
After the interviews had been completed, members of the research team read and coded the interviews
for emergent themes. It must be emphasised that although the authors believe that public trust is a
topic of crucial importance, specific questions about trust and trustworthiness were not part of the
original interview schedule (which was open-ended) and they did not “force” the data by asking
directed and potentially leading questions about trust and trustworthiness. Rather, they allowed
participants to reflect freely and then analysed the emergent themes for evidence of trust.
Given that trust is an internal state rather than something that can be easily articulated, it was
decided to code for “perceived trustworthiness” rather than for the presence or absence of “trust”. For
the purposes of coding, the authors drew on O’Neill’s notion of “trustworthiness”32 and defined the
components of perceived trustworthiness as:
• belief in the trustee’s desire/capacity to do good for the truster (beneficence);
• belief in the trustee’s desire/capacity to prevent harm to the truster (non-maleficence); and/or
• belief that the trustee can be left unsupervised to carry out its activities on behalf of the “truster”.
While the relationship between perceived trustworthiness, the state of trust and the process of
trusting is complex, for the purposes of this article the authors see perceived trustworthiness as at least
preliminary evidence of, or a marker for, the existence of trust.
While the primary interest was in attitudes to academic biomedical science and scientists and to
the academic biobanking profession, an effort was made to analyse also the perceived trustworthiness
of “science” in general; bureaucracies managing and governing biomedical science; commercial
research organisations; the general public; third parties with a non-research interest in research-
generated information (insurance companies, employers, forensics); and politicians. The aim of this
exercise was to determine not only the extent to which academic biobankers are perceived to be
trustworthy, but also whether this perceived trustworthiness (or otherwise) is generalised or limited to
academic researchers
RESULTS
Perceived trustworthiness of academic biobankers and their institutions
The lay participants in this study appeared to perceive academic biobankers and their institutions to be
highly trustworthy.
32 O’Neill O, Autonomy and Trust in Bioethics (Cambridge University Press, Cambridge, 2002).
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Perceptions of beneficence and non-maleficence
The biobanking profession was consistently seen to have both a desire and a capacity to do good for
society, and to prevent harm to tissue donors. Participants stated that they “trusted the profession to be
ethical” (CR) and “to do something … good” (C). Particular emphasis seemed to be on the
qualifications, training and knowledge with which clinicians and biomedical scientists are equipped
and on the respectability and wisdom inherent in academic research and training:
… medical people [are] qualified and have the background and the knowledge. [HA]
As a result, many participants appeared comfortable with biobanks having access to identifying
information about themselves which they believed would be used wisely and not abused:
I’ve probably got enough faith in human kind to say that my tissue would be looked after and not used
against me. [HA]
This belief appeared to be remarkably stable. Even when participants were alerted, over the course of
the interview, to possible abuses and acknowledged these possibilities (eg that “information could be
at risk” (P)), they seemed to consider these to be hypothetical risks, which were unlikely to eventuate
in reality:
I guess some people would have concerns about privacy … but, no, I don’t personally. [HA]
Perceptions of the ability to leave scientists unsupervised
Respondents did see a role for general “scientific guidelines” (HA) to “put the individual more at
ease” (IR) and expressed concern that effective scientific collaborations may not take place (HA) and
that donors may be put under pressure to participate:
I think there should be some regulation there … [that patients aren’t] just put under duress. [P]
Nonetheless, there was a consistent belief that academic scientists should not be overregulated from
outside their institutions or overburdened with “intensely intricate legislation” (IR) that would stifle
research:
I don’t want … laws to restrict what the scientists can do. [C]
Indeed, one participant, who argued for the need to regulate biobanking, based this on the argument
that clear laws concerning acceptable practice would protect, rather than control, biobankers and
thereby facilitate research (CR).
Participants placed their faith in the management structures within research institutions to ensure
that guidelines are established and followed:
[R]esearch institutes … run from the big hospitals, where … they have strict guidelines that they have
to follow in use and reporting and have to answer to governing bodies about what they’re doing. [HA]
Faith was also placed in scientific “advisory boards” for determining research priorities and ensuring
that tissue is used wisely and not wasted, misused, or collected unnecessarily:
Researchers would probably need to convince some sort of board that they had a legitimate … need for
the tissue and they wouldn’t be wasting it. [HA]
In keeping with their belief that biobankers can be left largely to their own devices, participants
expressed a willingness to allow biobanks to decide what use should be made of donated tissues. It
was argued that people should be asked at the outset whether they would like to participate in
research, but that open-ended consent was sufficient:
I think it should be part of the general consent … a rough idea of how it will be used. [HA]
[I]f you’ve already agreed that they can take it then there’s no need for you to be asked can they work
on it further. [P]
I think it’s up to the bank … to say, “Look, (a) we would like to keep it … to be involved in research,
at this stage we really don’t know … we may use it for general cancer research or specific … but we’d
really like your permission for it to be used as we see fit.” [HA]
Recurrent consent was deemed appropriate only where banks intended to use tissue for research that
was outside the original consent:
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I think that if it moves from one playing field to another playing field … jumps all the way over here for
something totally different … to what you thought … I think that I would like to know. [HA]
This stance was at times justified on the grounds that rigid consent requirements would create
excessive administrative burden and stifle valuable research:
Cause then it comes down to how much are we going to involve the researchers and do we want them
spending half the time cuddling the tissue donor, or do we want them actually in there doing the
research? [HA]
The need for at least initial consent was justified on the basis that certain types of research might
be unacceptable to certain groups. One participant thought that
possibly religion and ethnicity may be an issue that … the tumour banking would have to consider,
because … you might get people who say no … because it doesn’t fit in with their religious or moral
beliefs. [HA]
Cloning was frequently mentioned as a “contentious issue” (HA).33
But there was still a strong sense that biobankers themselves should make decisions about the use
of tissue, that an initial open-ended consent is sufficient and that it was unnecessary to give donors
significant amounts of detailed information about what would be done with their tissue.
Together, these views about external regulation and consent suggest that participants see
biobanking researchers as trustworthy.
Perceptions of the trustworthiness of other entities
As mentioned above, the present study wished to determine the extent to which the public perception
of trustworthiness extends to entities such as “science” in general (biomedical and biobanking
science), individual biobanking scientists and other groups (bureaucrats, insurance companies,
politicians, etc)
Individual scientists
Whereas biobankers as a profession, embedded in public institutions, were seen as highly trustworthy,
attitudes towards individual scientists were more ambivalent. Some participants seemed comfortable
with individual researchers or clinicians making decisions about tissue use, and were confident that
they would respect tissue and would ensure that tissue was not wasted. Others, however, mentioned
that individual researchers might be biased by their own personal research agenda when deciding on
research priorities. Individual clinicians or researchers were mentioned most noticeably in the context
of flagrant abuses of patient vulnerability or trust when, eg, researchers objectified patients, or caused
them distress eg by being “quite brutal in their forcing people to know and they don’t want to” (C).
Such individuals were labelled as “mad scientists”, “rogues”, “crooks” or “wealthy entrepreneurs who
are masquerading as doctors” (C). Here the impression given was that such individuals were not “real”
scientists or doctors, thereby again removing such untrustworthy behaviour from the realm of
biomedical science.
The biobanking endeavour
Like the academic biobanking profession and its institutions, the biobanking endeavour in the abstract
(ie the idea of biobanking as an endeavour rather than the practice of biobanking in reality) was
viewed positively. There appeared to be a great belief in the potential of biobanking to produce
outcomes “for the betterment of everybody” (P), particularly “to help people in the future” (C),
through “building up knowledge” (HA). In particular, participants emphasised that biobanking could
“prevent someone else getting sick in the future” (HA) by “identifying what sort of people might be
prone to getting it” (C) or by “develop[ing] … a test …. [to] make it an easy … diagnosis” [P), or “the
hope of a possible cure down the track” (P). In some instances patients even suggested that the
33 Existing literature suggests that it is unlikely that participants had significant understanding of cloning science and it is
possible that they may have been referring to the creation of a biological entity with interests (reproductive cloning): Australian
Government, Legislation Review: Prohibition of Human Cloning Act 2002 and the Research Involving Human Embryos Act
2002 (Canberra, 2005).
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banking of their tissue might benefit themselves or their family. Most participants seemed unable to
conceive of ways in which biobanking could produce harm, until negative possibilities were explicitly
mentioned by the interviewer. Even then, however, there appeared to be some presumption, the basis
of which was unclear, that these “science fictiony” (HA) possibilities were unlikely to occur. Thus,
comments in relation to the biobanking research endeavour emphasised the promissory aspect of
biobanking as a scientific endeavour.
The scientific endeavour
In contrast to their perceptions of biobanking science, participants seemed keenly aware that the
outcomes of science more generally were not always positive. Possibilities such as warfare (“to find
some way of mutating people’s genes … so that … nations could die out …” (P)), eugenics (“this
push to not have any imperfect children born” (C)) and reproductive cloning (“if there’s supposed to
be two of me … I just don’t believe in mucking around with Mother Nature” (P)) were mentioned.
However, such examples were usually positioned as evil outliers of what is an otherwise good
endeavour and were quickly passed by. This positioning was at times achieved by distinguishing
medical from non-medical science. Support for biomedical science more specifically was relatively
high, with participants often commenting that it has great potential to prevent or cure illness through
“incredible breakthroughs” (HA).
Other groups
The authors wished also to determine the extent to which public perceptions of trustworthiness extend
to those entities that actually or potentially interact with science, including the bureaucracies
managing and governing biomedical science; commercial research organisations; the general public;
third parties with a non-research interest in research-generated information (insurance companies,
employers, forensics); and politicians. It is beyond the scope of this article to describe these results in
detail, but they were essentially unsurprising. Commercial organisations were viewed with some
reserve. While some participants did acknowledge that commercial activities could produce some
benefit for the public, this was generally limited to the production of potentially useful drugs by
privately funded research institutes. Participants were concerned that privacy would not be adequately
protected by private industry. Consequently, many participants felt that it was important for donors to
be informed if research using their tissue might have a commercial component. Not surprisingly, third
parties with a commercial interest in research-generated information were strongly distrusted. When
asked if third parties such as insurance companies and employers should have access to tissue
samples, participants were wary and frequently commented that such organisations would misuse
tissue and should not be given access. In particular, participants expressed concern about the abuses
associated with the commercial profit motive. The existence of government bureaucracies in the form
of regulatory bodies is clearly necessary, given the assertion made by most participants that at least
minimal regulations should exist for biobanking. However, when commenting explicitly on
bureaucracies and bureaucrats, participants’ responses were overwhelmingly negative. Bureaucracies
in the form of government health services were criticised for not adequately consulting the community
about their needs, and for being selective in their protection of public interests. Government
regulation, despite being considered a necessity by many participants, was criticised for interfering
with research, and for potentially holding back scientific progress. The most unequivocally distrusted
group among those discussed was politicians. When asked whether politicians should be involved in
determining research priorities, participants reacted in an immediate and strongly negative manner.
INTERPRETATION
In summary, these results show that, for study participants:
• trust in the context of biobanking appears to accord with O’Neill’s notion of trustworthiness;
• academic biomedical scientists and their institutional ethics committees/advisory boards are seen
as trustworthy; and
• members of the public clearly distinguish between the profession of academic biomedicine and its
institutions; individual scientists; and the scientific/biobanking endeavour more generally.
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These findings also confirm that governmental bureaucracies, commercial organisations, the
general public and politicians are seen as variably trustworthy or untrustworthy in comparison to
academic biomedicine.
DISCUSSION
This section argues that, for those populations with high levels of trust in academic biomedicine, it is
important to respect this trust, utilise it, value it, protect it and ensure that it is, and continues to be,
warranted.
Respecting and utilising trust
There are two broad ways in which a public perception of high trustworthiness of academic
biobanking institutions can be viewed. On the one hand, it could be argued that the general public and
their representatives are naïve in placing their trust in academic biomedicine, or that their trust is
nothing more than blind faith. Such scepticism could be justified by arguing that institutions and
professions have at their disposal various means of blinding individuals to the ways in which their
autonomy and security are being compromised,34 or that individuals feel compelled to trust academic
biomedicine because of its creation of an “escalating spiral” of risk-related anxieties, and its
concomitant claim to be the only enterprise capable, through its own surveillance and research
processes, of legitimately and effectively modulating this risk.35 It could also be argued that tissue
donors are displaying what Giddens has called “sustained optimism”, which represents “a continued
faith in providential reason despite whatever danger threatens at the current time”.36 If this view is
taken, then it seems appropriate to continue with the current trend towards increasingly explicit
contracts (through, eg, recurrent and project-specific consent processes).
On the other hand, it could be argued that the academic biobanking professionals and their
institutions – in some settings at least – are genuinely trustworthy and that the lay perception is both
valid and appropriate. If this is the case, then it seems important to treat this trust with respect. To put
it another way, one could argue that the burden of justification should rest with those who assume both
the presence and appropriateness of public distrust, rather than those who recognise that, to some
extent at least, public trust in academic biobanking institutions is high, stable and at least potentially
justifiable.
One way of doing so (which is consistent with O’Neill’s notion of perceived trustworthiness as
including the belief that the trustee can be left unsupervised to carry out its activities on behalf of the
“truster”) would be to allow tissue donors to give open-ended consent if they so desire (or to authorise
specific uses of their tissue).37 While recurrent, individual consent is frequently justified on the basis
that it respects and protects research subjects’ autonomy, insisting on individual project-specific
consent in this context may actually be paternalistic and diminish research subjects’ autonomous
choice to place their trust in ethics committees/advisory boards and to give open-ended consent, thus
eliminating the research subject’s freedom to act as a morally and politically competent citizen.38 The
present authors agree with Hoeyer and Lynoe, who argue that “the choice offered when introducing
informed consent as a central regulatory practice eliminates another choice: whether to trust the
authorities to manage the ethical problems associated with research”.39
In practice, this would involve halting, and perhaps even reversing, regulation that demands
recurrent, project-specific consent and allowing academic institutional ethics committees and/or
34 Crawford, n 14; Lupton D, Risk (Routledge, London, 1999).
35 Bauman, n 14 (1992); Bauman, n 14 (1999); Crawford, n 14; Hacking, n 14; Sontag, n 14.
36 Giddens A, The Consequences of Modernity (Stanford University Press, Stanford, 1990).
37 Caulfield T, Upshur REG and Daar A, “DNA Databanks and Consent: A Suggested Policy Option Involving an Authorization
Model” (2003) 4 BMC Med Ethics 1.
38 Bauman Z, Postmodern Ethics (Blackwell, Oxford, 1993); Bauman, n 14 (1999); Hansson M, “Combining Efficiency and
Concerns about Integrity When Using Human Biobanks” (2006) 37 Stud Hist Philos Biol Biomed Sci 520; Berg K, “DNA
Sampling and Banking in Clinical Genetics and Genetic Research” (2001) 20 New Genet Soc 59.
39 Hoeyer and Lynoe, n 23 at 19.
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associated advisory committees40 more, rather than less, freedom in determining the degree to which
consent needs to be project-specific and the uses to which donated tissue might be put. Indeed, such
freedom might even be codified as part of legislation, as is the case with the recent amendments to
Australian law regarding research using cloned embryos.41
Valuing trust
In addition to believing that (warranted) trust should be respected and utilised, the authors would
argue that such trust is highly valuable and should be seen as such. While there is little doubt that
explicit contracts in the form of detailed, recurrent consent may instil a sense of confidence (if not
trust) in researchers and may well be a route to increasing the public’s willingness to participate in
research, trust can do things that contracts cannot:
• trust can be unconscious;
• trust does not demand that all the terms of a relationship be outlined in advance, meaning that
social agents can act without excessive constraint in situations characterised by uncertainty and
complexity;42 and
• as feminist43 and communitarian44 scholars have long observed, trust contributes to our sense of
security and wellbeing, and gives us a basis for moral action in a way that can never be achieved
through “contractarian-Kantian moral theories”45 and their associated legalistic social practices.
In the biomedical context, a culture of trust might strengthen the bond of patients with clinicians and
researchers, and contribute to feelings of solidarity with medicine more generally.
For these reasons, the authors believe that, unless it can be unequivocally demonstrated that
public trust in academic institutions is naïve and unwarranted, it is essential to respect this trust and to
view public trust as a precious, irreplaceable resource. This brings us to the question of how best to
protect the public’s high trust in academic biobankers and their institutions and to ensure that this trust
continues to be warranted.
Protecting trust and ensuring that it is warranted
To say that public trust is relatively stable, warranted, valuable and worthy of respect is not to say that
this trust does not need to be protected.46 Nor does the presence of trust mean that this trust will
always be warranted. As Baier cautions, not all things that thrive when there is trust between people
are things that should be encouraged, and there are immoral as well as moral trust relationships.47 Put
another way, freedom is something that can, and should, be contested48 and it is important to ensure
that trust in academic biobanking is, in fact, a moral trust relationship and that the discretionary power
given to academic institutions is deserved. The present authors would in no way, therefore, advocate a
return to unquestioned faith in scientific authority.
In practice, this need to protect and justify trust might lead us, in a circular fashion, back to the
current situation of increasingly explicit (consent) contracts. But caution against such a reflex is
40 At this stage the exact composition of these bodies is still an open question. Participants did not spontaneously advocate or
oppose community involvement and, when asked, their responses were variable. When community representatives were
mentioned, it was not clear who these representatives were considered to be, ie whether they had scientific education, were
members of a relevant disease group or were health advocates. Therefore no conclusions can be drawn at this stage as to whether
such “committees” or “boards” entrusted with internal regulation of tissue banking would consist solely of members of the
scientific and medical professions.
41 Australian Government, n 33.
42 Luhmann N, Trust and Power (Wiley, Chichester, 1979).
43 Gilligan C, In a Different Voice (Harvard University Press, Cambridge, 1982); Hoeyer, n 13.
44 Little M, Community, Security and Human Flourishing (Centre for Values, Ethics and the Law in Medicine, Sydney, 2004);
Sandel M (ed), Liberalism and Its Critics (Blackwell, Oxford, 1984).
45 Bauman, n 38; O’Neill, n 32; Baier, n 19..
46 Godard, Marshall and Laberge, n 27.
47 Baier, n 19.
48 Bauman, n 38.
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advisable. First, as discussed above, the authors believe that trust should be respected and valued, and
this may entail allowing open-ended consent. Secondly, the relationship between trust and regulation
is complex, and an “audit culture” demanding complete transparency may, in fact, decrease rather than
increase trust. Indeed, demands for recurrent consent when this is not what people want can decrease
trust by suggesting both lack of respect for autonomy and by suggesting that ethical review systems
are unreliable.49 Similarly, an “audit culture” may decrease the trustworthiness of academic
institutions by obscuring more substantive ethical issues50 and by reducing moral behaviour to
instrumental compliance with institutional requirements rather than considered reflection on ethical
practice. As O’Neill observes, demanding that people adhere to legalistic protocols can lead people to
behave in ways that “obstruct rather than contribute to the outcomes and standards demanded”.51.While
it is not argued here that regulation is directly or primarily responsible for erosion in trust or
trustworthiness, a relationship cannot be ruled out.
The current authors argue, therefore, for a system in which external oversight of institutional
ethics committees is maintained, and even strengthened, to ensure that biobanks do not “do violence”
to the trust with which they are imbued,52 but not to the extent that these ethics committees, together
with advisory boards, cannot engage with donors and researchers to determine appropriate consent
procedures and uses of donated tissue. Like O’Neill, they argue not for complete disbanding of
regulatory structures, and return to a paternalistic “club culture”, but rather for a combination of
“intelligent accountability” and “intelligent trust”, in which to “consider which forms of accountability
best support which forms of trust”.53 Institutional ethics committees should, therefore, be required to
follow human tissue and privacy legislation, which should be as stringent as necessary – particularly
in relation to third party access to genetic information54 - and should be monitored to ensure that they
are operating effectively and to ensure that the procedures governing research are “open to public and
democratic control”.55 As Hoeyer and Lynoe point out, it is important to put in place the safeguards
necessary for a biobank to “prove itself trustworthy”.56 We should, they argue, place “less focus on the
intentionality of donors and more on the responsibility of those institutions in which people place their
trust through their acts”.57 And, like Whong-Barr, the authors argue that the focus of biobanking
should be moved from autonomy to trust and, in particular, to O’Neill’s notion of trustworthiness.58
The current authors are not, therefore, against “procedural safeguards to maintain public trust”59
such as setting up a licensing system for tissue collections or having institutional ethics committees
report to a central body, particularly with respect to their associations with commercial researchers and
other third parties, and to ensure that all populations enjoy the benefits of research.60 Indeed, their
suggested approach to consent underscores the need for more stringent mechanisms for “protection of
49 Hansson, n 13.
50 Petersen, n 18.
51 O’Neill, n 32.
52 Dixon-Woods, Ashcroft, Jackson, Tobin et al, n 20.
53 O’Neill O, “Accountability, Trust and Informed Consent in Medical Practice and Research” (2004) 4 Clin Med 269 at 271.
54 Hansson, n 13.
55 Hansson, n 38.
56 Hoeyer and Lynoe, n 23 at 15.
57 Hoeyer and Lynoe, n 23 at 21.
58 Whong-Barr M, “Informed Consent and the Shaping of British and US Population-based Genetic Research” in Guston D and
Sarawitz D (eds), Shaping Science & Technology Policy: The New Generation of Research (University of Wisconsin Press,
Madison, 2004).
59 Da Rocha AC and Seoane JA, “Alternative Consent Models for Biobanks: The New Spanish Law on Biomedical Research”
(2008) 22 Bioethics 440.
60 Hoeyer K, Olofsson BO, Mjorndal T and Lynoe N, “Informed Consent and Biobanks: A Population-based Study of Attitudes
Towards Tissue Donation for Genetic Research” (2004) 32 Scand J Public Health 224.
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the act of donation and the rights of the donor”.61 The argument has been made elsewhere for using a
“trusted intermediary” or “charitable trust model” for genomic biobanking62 so as to place biobanks in
“safe hands”63 and this research supports such an approach. It is crucial, therefore, to ensure that
institutional ethics committees are appropriately constituted, sufficiently expert, adequately monitored,
and aware of the need to consider the vulnerabilities of research participants, the need to facilitate
research, and the values of the community.
In addition, the current authors would argue that it is crucial to secure at least initial consent and
to give people the option to withdraw, as a means not only of allowing them to exercise their
autonomy but also as a “ceremony” that can help to “secure trust”.64 Biobanks would also need to
maintain ongoing communication, if not with individual donors then at least with communities of
tissue donors and the general public. While communication may be difficult in the context of multi-site
tissue storage networks and research projects where distant, “faceless commitments” are the norm,65
they believe that at least periodic contact should be maintained such that communities can be informed
of the activities of biobanks (particularly where there is commercial involvement).
Moreover, this communication needs to be two-way so that donor expectations can be managed to
avoid the “therapeutic misconception”, and so that their preferences and concerns can be considered.
This two-way communication process could be mediated by community advisory boards, or “trustee
infrastructures”66 linked to institutional ethics committees, and accessible to donors. This is essential
if trust is to be meaningful, because perceptions of trustworthiness can change constantly throughout a
relationship and discourse is essential if the donor community (the trusters) is to remain convinced
that academic institutions (trustees) continue to have their interests at heart and the capacity to fulfil
those interests without supervision. Periodic contact with donor communities is thus crucial in order to
show research participants that their interests are being taken seriously, and to obtain information
about community values.67 This kind of procedural approach differs markedly from the notion of
consent as a single or recurrent event which is focused only on the individual and is preoccupied with
obtaining written permission. Such standard “consent-getting” processes tell the research participant
little, if anything, about the broad goals of the research; and tell the researcher little, if anything, about
the values of the research participant. It is only through a two-way flow of information that
meaningful relationships of trust can be developed and sustained. The current authors agree with
Levitt and Weldon who recognise that public trust in relation to biobanking, and the role of regulation
in maintaining trust, is complex and argue that “rather than seeing trust as a measurable goal or
performance indicator … it needs to be seen as an emergent property of good social relationships that
are built up over time”.68
61 Haddow, Cunningham-Burley, Bruce and Parry, n 13 at 148.
62 Tutton, Kaye and Hoeyer, n 15; Winickoff R, “The Charitable Trust as a Model for Genomic Biobanks” (2003) 349 NEJM
1180; Lipworth W, Ankeny R and Kerridge I, “Consent in Crisis: The Need to Reconceptualize Consent to Tissue Banking
Research” (2006) Intern Med J 124.
63 Levitt and Weldon, n 12.
64 Dixon-Woods, Wilson, Jackson, Cavers et al, n 20; Dixon-Woods, Ashcroft, Jackson, Tobin et al, n 20; Hansson MG,
Dillner J, Bartram CR, Carlson JA et al, “Should Donors be Allowed to Give Broad Consent to Future Biobank Research?”
(2006) 7 Lancet Oncol 266; Helgesson G and Johnsson L, “The Right to Withdraw Consent to Research on Biobank Samples”
(2005) 8 Med Health Care Philos 315.
65 Giddens, n 36.
66 Ashburn, Wilson and Eisenstein, n 5; McCarty, Chapman-Stone, Derfus, Giampietro et al, n 27.
67 Lipworth, Ankeny and Kerridge, n 62.
68 Levitt and Weldon, n 12 at 320.
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Consistency with other research
The approach suggested here is consistent with a number of other studies which have shown that the
majority of tissue donors are not particularly interested in the detailed information provided to them;69
are more concerned about issues other than consent (eg distributive justice)70 and want to be asked
initially whether they are willing to donate but are then happy to give open-ended consent to future
research71 (or, at least, to give open-ended consent for a specified period of time)72 or for a broad area
of research such as cancer research.73
Limitations
While the degree of similarity among study participants was striking, this is a small qualitative study
that focuses on a particular form of biobanking (collection of diseased tissue for cancer research) in a
particular health system, and it cannot be said with certainty that these results would generalise
beyond this local study population or to other kinds of biobanking research. It is possible, eg, that trust
is “embedded in the state-citizen relationship”74 and that people in countries such as Australia and
Sweden, with publicly funded and publicly accessible health systems, have more trust in academic
institutions.75 Similarly, it is conceivable that people are more willing to give freedom to those
carrying out disease-specific medical research than to those involved with larger population genetic
databases which may be perceived to be less clear in their aims and objectives, less obviously relevant
to healthy donors, more politically and commercially oriented or susceptible to government or
commercial misuse, and more likely to be used for dangerous (eg cloning or bioterrorism),
stigmatising or exploitative research.76 In a study of parents of children with cancer, Dixon-Woods et
al observed the presence of “thick trust” developed through months or years of close contact with
health professionals;77 and Hoeyer has similarly observed that tissue donation to a Swedish biobank
reflects “reflects a mutual contextual trust established between nurse and patient, state and citizen”.78
The current authors recognise also that in some studies a significant minority of people express a
desire for recurrent, project-specific consent, particularly for commercially oriented research.79
Finally, they recognise that public responses to perceived breaches of trust are variable. Divergent
responses across countries to genetically modified organisms and Bovine Spongieform Encephalopathy
69 Barr, n 20; Hoeyer K, “‘Science is Really Needed – That’s All I Know’: Informed Consent and the Non-verbal Practices of
Collecting Blood for Genetic Research in Northern Sweden” (2003) 22 New Genet Soc 229.
70 Hoeyer, Olofsson, Mjorndal and Lynoe, n 60.
71 Wendler D and Emanuel E, “Research on Stored Biological Samples: What do Sources Think?” (2002) 162 Arch Intern Med
1457; Richards, Ponder, Pharoah, Everest et al, n 20; Kettis-Lindblad, Ring, Viberth and Hansson, n 29; Kaphingst, Janoff,
Harris and Emmons, n 27; Hoeyer, Olofsson, Mjorndal and Lynoe, n 60; Dixon-Woods, Wilson, Jackson, Cavers et al, n 20;
Chen DT, Rosenstein DL, Muthappan P, Hilsenbeck SG et al, “Research with Stored Biological Samples: What do Research
Participants Want?” (2005) 165 Arch Intern Med 652; Beskow and Dean, n 28; Goodson and Vernon, n 25; Jack A and
Womack C, “Why Surgical Patients Do Not Donate Tissue for Commercial Research: Review of Records” (2003) 327 BMJ
262; Stegmayr B and Asplund K, “Informed Consent for Genetic Research on Blood Stored for More Than a Decade: A
Population Based Study” (2002) 325 BMJ 634.
72 Shickle DR, Hapgood R, Carlisle J, Shackley P et al, “Public Attitudes to Participating in a UK BioBank: A DNA Bank,
Lifestyle and Morbidity Database on 500,000 Members of the UK Public Aged 45-69” in Finn B (ed), Populations and
Genetics: Legal and Socio-Ethical Perspectives (Martinus Nijhoff Publishers, Boston, 2003).
73 Goodson and Vernon, n 25.
74 Hoeyer, n 13.
75 Hoeyer, n 69; Barr, n 20.
76 Haddow, Cunningham-Burley, Bruce and Parry, n 13; Richards, Ponder, Pharoah, Everest et al, n 20.
77 Dixon-Woods, Wilson, Jackson, Cavers et al, n 20.
78 Hoeyer, n 69 at 238.
79 Hoeyer, Olofsson, Mjorndal and Lynoe, n 60; Nilstun T and Hermeren G, “Human Tissue Samples and Ethics – Attitudes of
the General Public in Sweden to Biobank Research” (2006) 9 Med Health Care Philos 81; Secko DM, Preto N, Niemeyer S and
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are just two examples of variations in the degree of trust in regulatory authorities. Like others,80 the
authors wish to underscore the need for contextually specific consultation which takes into account
both the population and the kind of tissue collection (eg a disease bank versus a population database)
and for at least an initial consent in which individuals can express their preferences.
Bearing the above qualifications in mind, the authors believe that these results, where they are
demonstrated to apply, provide justification for an approach to biobanking which gives increased
freedom to highly trusted academic researchers and their institutions. At the very least, high levels of
trust would need to be taken into account in the development of local biobanking policy. They have
suggested one way in which this trust might be utilised (relating to consent processes) but emphasise
that they are not biobanking researchers and do not have a vested interest in this particular outcome
(they are concerned by the emphasis on liberal individualism in biomedical ethics, but recognise that
this has emerged for a reason). The authors also note that this approach may be applicable to
biomedicine more generally and might change the way people think about any form of open-ended
research, which includes research using medical records and test results.
Importantly, increasing the freedom of academic researchers (under the watch of their externally
regulated ethics committees) would not necessarily require changes to the law or to ethical guidelines,
many of which allow project-specific consent to be waived under certain circumstances. What would
be required, however, is a fundamental change in attitudes among researchers and ethics committees
such that population preferences are accorded at least as much weight as are theoretical concerns, even
if this means that there is some local variation in practice, and so that decisions based upon population
preferences (such as the decision to waive project-specific consent requirements) can be made by
research ethics committees with confidence that their actions are both legally and ethically sound.
80 Artizzu, n 4; Godard, Marshall and Laberge, n 27.
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